



Published in final edited form as:

*Chem Commun (Camb)*. 1999 ; 1999(17): 1743–1744. doi:10.1039/A904533C.

## A stereoselective synthesis of (—)-tetrahydrolipstatin

Arun K. Ghosh and Chunfeng Liu

Department of Chemistry, University of Illinois at Chicago, 845 W. Taylor Street, Chicago, Illinois 60607, USA

### A stereoselective synthesis of (2)-tetrahydrolipstatin has been accomplished utilizing olefin metathesis of an acrylate ester as the key step.

Tetrahydrolipstatin **1**, a member of the lipstatin class of blactone microbial agents, is a potent and irreversible inhibitor of pancreatic lipase.<sup>1</sup> The lipase enzyme is responsible for the digestion of fat in the diet of humans.<sup>2</sup> The strained  $\beta$ -lactone functionality of **1** is critical to its lipase inhibitory properties. The inactivation mechanism involves an irreversible acylation of the active site serine residue of pancreatic lipase by the blactone moiety.<sup>3</sup> Recent clinical studies have revealed that treatment with **1** along with diet modifications have led to sustained weight loss in humans.<sup>4</sup> Indeed, Hoffman-La Roche Laboratories have now introduced (2)-tetrahydrolipstatin under the trade name Xenical® as an anti-obesity agent. The important biological properties along with its unique structural features have stimulated interest in the synthesis of **1** and its structural variants.<sup>5</sup> Herein we report an asymmetric synthesis of (2)-tetrahydrolipstatin. The key synthetic strategy involves a stereoselective construction of a *syn*-1,3-diol synthon by olefin metathesis, stereoselective epoxidation and regioselective epoxide reduction followed by its elaboration to **1**.

As depicted in Scheme 1, we planned to construct the blactone ring from the corresponding  $\beta$ -hydroxy acid derivative **2**. The elaboration of the *syn*-1,3-diol functionality and stereoselective introduction of the C-2 alkyl chain in **2** would be achieved from the  $\alpha$ ,  $\beta$ -unsaturated  $\delta$ -lactone **3**. The intermediate **3** would be derived from ring-closing metathesis of the corresponding acrylate ester **4**. Recently, a number of convenient syntheses of various  $\alpha$ , $\beta$ -unsaturated  $\gamma$ - and  $\delta$ -lactones have been reported involving ring closing metathesis of acrylates utilizing Grubbs' catalyst.<sup>6</sup> The broad synthetic utility of Grubbs' catalyst is now well established.<sup>7</sup> The key starting material, homoallylic alcohol **5** was prepared in multigram quantities by Keck's enantioselective allylation of dodecanal employing a catalytic amount (10 mol%) of (*R*)-BINOL and Ti(OPr<sup>*i*</sup>)<sub>4</sub> to furnish **5** in 90% yield.<sup>8</sup> The optical purity of the alcohol **5** [92% ee,  $[\alpha]_D^{23} - 6.3$  (*c* 1.23, CHCl<sub>3</sub>)] was obtained by formation of the Mosher ester and <sup>19</sup>F NMR analysis.<sup>9</sup> Reaction of **5** with acryloyl chloride (1.2 equiv.) and Et<sub>3</sub>N (3 equiv.) in the presence of a catalytic amount of DMAP in CH<sub>2</sub>Cl<sub>2</sub> provided the acrylate ester **4** in 91% yield after silica gel chromatography (Scheme 2). Olefin metathesis of **4** with commercially available Grubbs' catalyst (10 mol%) in the presence of Ti(OPr<sup>*i*</sup>)<sub>4</sub> (0.3 equiv.) in refluxing CH<sub>2</sub>Cl<sub>2</sub> (0.007 M solution) for 15 h afforded the  $\alpha$ , $\beta$ -unsaturated  $\delta$ -lactone **3** in 93% yield. Consistent with our earlier report, exposure of

acrylate ester **4** to Grubbs' catalyst (10 mol%) in CH<sub>2</sub>Cl<sub>2</sub> for 15 h in the absence of Ti(OPr<sup>i</sup>)<sub>4</sub> resulted in low conversion of lactone **3** (50% by <sup>1</sup>H NMR) with a substantial amount of unreacted starting material remaining.<sup>6b</sup> Epoxidation of lactone **3** was carried out with alkaline H<sub>2</sub>O<sub>2</sub> in MeOH at 23 °C for 1 h. Acidification, extractive work-up followed by azeotropic removal of the water by heating in benzene furnished the epoxide **6** as a single isomer. Epoxidation of **3** proceeded stereoselectively from the less hindered β-face.<sup>10</sup> Exposure of epoxide **6** to PhSeSePh and NaBH<sub>4</sub> in Pr<sup>i</sup>OH at 0 °C in the presence of AcOH resulted in regioselective reduction of the epoxide to afford the β-hydroxy-lactone **7** in 83% yield (from **3**) after silica gel chromatography.<sup>11</sup> Thus, the sequence of reactions involving olefin metathesis, stereoselective epoxidation and regioselective epoxide reduction constitute an effective protocol for the *syn*-1,3-diol synthon **9**. For introduction of the C-2 alkyl chain, attempted direct alkylation of the β-hydroxylactone **7** under a variety of reaction conditions was unsuccessful. Therefore, the elaboration of the C-2 side chain was carried out by an alternate route using Seebach's asymmetric alkylation of β-hydroxy esters.<sup>12</sup>

The β-hydroxy lactone **7** was first protected as a TBDMS ether **8** by treatment with TBDMSCl and Pr<sup>i</sup><sub>2</sub>NEt in DMF at 23 °C for 12 h. Lactone **8** was converted to β-hydroxy ester **10** in a three step sequence involving (i) opening of the lactone ring by exposure to Et<sub>3</sub>N in MeOH at 23 °C for 12 h, (ii) protection of the resulting δ-hydroxy methyl ester as THP ether, and (iii) removal of the TBDMS group by treatment with Bu<sub>4</sub>NF in THF in the presence of AcOH at 23 °C for 5 h (60% from **7**). The C(2) hexyl side chain was then introduced by an asymmetric alkylation of the β-hydroxy ester **10** (Scheme 3). Thus, methyl ester **10** was treated with LDA (2.2 equiv.) in the presence of HMPA (5 equiv.) in THF at -78 °C and the reaction mixture was warmed to -50 °C for 2 h. The resulting dianion was cooled to -78 °C and reacted with hexyl iodide (2 equiv.) at -78 to 0 °C for 6 h to afford the alkylated product **11** in 85% yield (based upon 30% recovery of starting material). The removal of the THP ether group in **11** revealed excellent diastereoselectivity (ratio 22:1 by <sup>13</sup>C NMR).<sup>13</sup> The stereochemical course of such alkylation processes has been well-established previously.<sup>12</sup>

Saponification of ester **11** with aqueous LiOH followed by exposure of the resulting acid to PhSO<sub>2</sub>Cl in pyridine at 0 °C for 8 h, as described by Barbier and Schneider, afforded the β-lactone **12** in 84% yield (from **11**).<sup>5k</sup> The removal of the THP group by treatment with PPTS in EtOH at reflux furnished the (5*S*)-hydroxy β-lactone **13** [ $[\alpha]_D^{23} - 14.4$  (*c* 1.2, CHCl<sub>3</sub>)] as a single isomer. Attempted esterification with *N*-formylleucine under a variety of conditions failed to provide satisfactory results. To complete the synthesis, *N*-formylleucine was introduced by an alternate protocol as described by Uskokovic *et al.*<sup>5g</sup> Esterification of **13** with Cbz-leu and DCC in the presence of DMAP provided the Cbz derivative **14** in 95% yield.<sup>14</sup> Catalytic hydrogenation of **14** over 10% Pd-C followed by *N*-formylation of the resulting amine with formic acetic anhydride in THF at 23 °C for 1 h furnished the synthetic (2)-tetrahydrolipstatin **1** [ $[\alpha]_D^{23} - 33.8$  (*c* 1.4, CHCl<sub>3</sub>); lit.,<sup>1</sup>  $[\alpha]_D^{23} - 34.45$ , (*c* 1, CHCl<sub>3</sub>)]. Spectral data (IR and 400 MHz <sup>1</sup>H NMR) for the synthetic tetrahydrolipstatin are identical to those reported for the natural product.<sup>1</sup>


In summary, an asymmetric synthesis of (—)-tetrahydrolipstatin has been accomplished. A number of key features of this synthesis are noteworthy; a Keck enantioselective allylation of dodecanal, olefin metathesis of an acrylate ester to an unsaturated  $\delta$ -lactone, elaboration of this lactone to a *syn*-1,3-diol synthon and Seebach's asymmetric alkylation of a  $\beta$ -hydroxy ester.

## Acknowledgments


Financial support for this work was provided by the National Institutes of Health (GM 55600).

## Notes and references


1. Weibel EK, Hadvary P, Hochuli E, Kupfer E and Lengsfeld H, *J. Antibiot.*, 1987, 40, 1081; [PubMed: 3680018] Hadvary P, Lengsfeld H and Wolfer H, *Biochem. J.*, 1988, 256, 357. [PubMed: 3223916]
2. Hogan S, Fleury A, Hadvary P, Lengsfeld H, Meier MK, Triscari J and Sullivan AC, *Int. J. Obes.*, 1987, 11, 35 (suppl. 3). [PubMed: 3440690]
3. Hadvary P, Sidler W, Meister W, Vetter W and Wolfer H, *J. Biol. Chem.*, 1991, 266, 2021. [PubMed: 1899234]
4. Drent ML and van der Veen EA, *Obes. Res.*, 1995, 3 (suppl. 4), 623S. [PubMed: 8697067]
5. (a) Paterson I and Doughty VA, *Tetrahedron Lett.*, 1999, 40, 393; (b) Fleming I and Lawrence NJ, *J. Chem. Soc., Perkin Trans 1.*, 1998, 2679; (c) Giese B and Roth MJ, *J. Braz. Chem. Soc.*, 1996, 7, 243; (d) Pommier A, Pons JM, Kocienski PJ and Wong L, *Synthesis*, 1994, 1294; (e) Hanessian S, Tehim A and Chen P, *J. Org. Chem.*, 1993, 58, 7768; (f) Case-Green SC, Davies SG and Hedgecock CJR, *Synlett*, 1991, 781; (g) Chadha NK, Batcho AD, Tang PC, Courtney LF, Cook CM, Wovkulich PM and Uskokovic MR, *J. Org. Chem.*, 1991, 56, 4714; (h) Fleming I and Lawrence NJ, *Tetrahedron Lett.*, 1990, 31, 3645; (i) Pons J and Kocienski PJ, *Tetrahedron Lett.*, 1989, 30, 1833; (j) Barbier P and Schneider F, *J. Org. Chem.*, 1988, 53, 1218; (k) Barbier P and Schneider F, *Helv. Chim. Acta.*, 1987, 70, 196; (l) Barbier P, Schneider F and Widmer U, *Helv. Chim. Acta.*, 1987, 70, 1412.
6. (a) Nicolaou KC, Rodriguez RM, Mitchell HJ and van Delft FL, *Angew. Chem., Int. Ed.*, 1998, 37, 1874; (b) Ghosh AK, Cappiello J and Shin D, *Tetrahedron Lett.*, 1998, 39, 4651; (c) Cossy J, Bauer D and Bellosta V, *Tetrahedron Lett.*, 1999, 40, 4187 and references cited therein.
7. Wright DL, *Curr. Org. Chem.*, 1999, 3, 211; Grubbs RH and Chang S, *Tetrahedron*, 1998, 54, 4413; Armstrong SK, *J. Chem. Soc., Perkin Trans 1*, 1998, 371; Schuster M and Blechert S, *Angew. Chem., Int. Ed. Engl.*, 1997, 36, 2037 and references cited therein. For recent reviews, see:
8. Keck GE, Tarbet KH and Geraci LS, *J. Am. Chem. Soc.*, 1993, 115, 8467; Keck GE and Krishnamurthy D, *Org. Synth.*, 1997, 75, 12.
9. Dale JA, Dull DL and Mosher HS, *J. Org. Chem.*, 1969, 34, 2543.
10. Takano S, Shimazaki Y, Sekiguchi Y and Ogasawara K, *Synthesis*, 1989, 539.
11. Miyashita M, Suzuki T and Yoshikoshi A, *Tetrahedron Lett.*, 1987, 28, 4293; Miyashita M, Hoshino M, Suzuki T and Yoshikoshi A, *Chem. Lett.*, 1988, 507.
12. Seebach D, Aebi J and Wasmuth D, *Org. Synth.*, 1985, 63, 109.
13. Alkylation of the corresponding  $\beta$ -hydroxy ester containing an anti-dbenzyloxy group proceeded with excellent diastereoselectivity (40+1). [ref. 5(e)]. Thus, the stereochemistry of the remote alkoxy group has little influence on the stereochemical outcome of this alkylation process.
14. All new compounds gave satisfactory spectroscopic and analytical results.



Scheme 1.

**Scheme 2.**

*Reagents and conditions:* i, CH<sub>2</sub>=CHCOCl, Et<sub>3</sub>N, DMAP, 23 °C (91%); ii, (PCy<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>Ru=CHPh (10 mol%), Ti(OPr<sup>i</sup>)<sub>4</sub> (0.3 equiv.), CH<sub>2</sub>Cl<sub>2</sub>, 40 °C (93%); iii, aq. NaOH, H<sub>2</sub>O<sub>2</sub>, 23 °C; iv, PhSeSePh, NaBH<sub>4</sub>, Pr<sup>i</sup>OH, AcOH, 0 °C (83%); v, TBDMSCl, Pr<sup>i</sup><sub>2</sub>NEt, DMF, 25 °C (98%).

**Scheme 3.**

*Reagents and conditions:* i, Et<sub>3</sub>N, MeOH, 23 °C, 12 h (75%); ii, DHP, PPTS, 8 h; iii, Bu<sub>4</sub>NF, THF, AcOH, 25 °C, 5 h (60% from **7**); iv, LDA, HMPA, C<sub>6</sub>H<sub>13</sub>I, THF, -78 to 0 °C, 6 h (70% conversion, 85%); v, aq. LiOH, 25 °C, 12 h, H<sup>+</sup>; vi, PhSO<sub>2</sub>Cl, Py, 0 °C, 8 h (84% from **11**); vii, PPTS, EtOH, reflux, 3 h (90%); viii, Cbz-Leu, DCC, DMAP (95%); ix, H<sub>2</sub>, Pd-C, 12 h; x, AcOCHO, THF, 25 °C, (87%).